-
Product Insights
Keratoconjunctivitis Sicca (Dry Eye): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Keratoconjunctivitis Sicca (Dry Eye) - Global Clinical Trials Review, 2026" provides an overview of Keratoconjunctivitis Sicca (Dry Eye) Clinical trials scenario. This report provides top line data relating to the clinical trials on Keratoconjunctivitis Sicca (Dry Eye). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Sector Analysis
Myopia and Pediatric Myopia Progression: Market View, Current and Future Competitive Landscape
Understand the Future of the Myopia Therapeutics Market Myopia and pediatric myopia progression are becoming increasingly important areas within ophthalmology. This report helps you understand how the competitive landscape is evolving across treatments, pipeline assets and clinical activity. You will gain insight into disease prevalence, treatment approaches and pipeline development. Moreover, the report highlights how innovation is shaping the future of therapeutics in this space. As a result, you can better assess where opportunities may emerge across the market. Report...
-
Product Insights
Uveitis - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Uveitis - Global Clinical Trials Review, 2026" provides an overview of Uveitis Clinical trials scenario. This report provides top line data relating to the clinical trials on Uveitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Retinitis Pigmentosa: Market View, Current and Future Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Retinitis Pigmentosa Therapeutics. • In 2024 and 2029, China is anticipated to have the highest number of diagnosed prevalent cases of RP, representing a large portion of global cases. • Currently, the RP market is largely reliant on off-label and symptomatic approaches. • The RP pipeline holds 102 molecules, with no assets in the pre-registration stage, four assets in Phase III development, and another 21 in...
-
Sector Analysis
Age-Related Macular Degeneration Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
The table below presents the key metrics for age-related macular degeneration (AMD) in the seven major pharmaceutical markets (7MM) covered in this report—the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan—during the forecast period from 2024–34. In 2024, GlobalData estimated the total AMD market to be valued at $7.8 billion across the 7MM, with the US accounting for 67.2% of the market. The five major European markets (5EU) (France, Germany, Italy, Spain, and UK) accounted for 28.9%...
-
Sector Analysis
Age-Related Macular Degeneration: 68-Market Analysis and Sales Forecast tp 2034
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Age-Related Macular Degeneration (AMD) market. Across the 68 markets, sales in the AMD market were $8.9 billion in 2024, growing to $24.1 billion in 2034. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 87.0% and 85.2% in 68-market sales in 2024 and 2034, respectively.
-
Sector Analysis
Retinal Vein Occlusion: Market View, Current and Future Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Retinal Vein Occlusion Therapeutics. • In 2024 and 2029, China is anticipated to have the highest number of diagnosed prevalent cases of BRVO, representing a large portion of global cases. • Currently, the RVO market lacks disease-modifying therapies, as no cure can reverse the blockage itself. Current treatments focus on managing complications like macular edema and neovascularization to stabilize vision and prevent further loss. • The RVO pipeline...
-
Product Insights
Dry (Atrophic) Macular Degeneration: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Dry (Atrophic) Macular Degeneration - Global Clinical Trials Review, 2025" provides an overview of Dry (Atrophic) Macular Degeneration Clinical trials scenario. This report provides top line data relating to the clinical trials on Dry (Atrophic) Macular Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Sector Analysis
Age-Related Macular Degeneration Epidemiology Analysis and Forecast to 2034
Age-related macular degeneration (AMD) is a chronic, progressive ophthalmological condition characterized by the gradual degeneration of the macula, the specialized area of the retina responsible for high-acuity central vision. It is recognized as the predominant cause of significant and irreversible vision loss among the older demographic. AMD is clinically staged as early, intermediate, and late. Late AMD, representing the advanced phase of the disease, is further subcategorized into late dry AMD (geographic atrophy) and wet AMD (neovascular AMD) (National Eye...
-
Sector Analysis
Uveitis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the uveitis market through 2033. There will be an overall increase in the diagnosed prevalent cases of uveitis in the 7MM across the forecast period. Across the 7MM, the mainstay treatment for uveitis involves the use of anti-inflammatory therapies. Significant clinical unmet needs remain in the uveitis market. The late-stage uveitis pipeline consists of six agents. The uveitis market in the 7MM was valued at...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.